WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012097238) IL-27 ANTAGONISTS FOR TREATING INFLAMMATORY DISEASES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/097238    International Application No.:    PCT/US2012/021224
Publication Date: 19.07.2012 International Filing Date: 13.01.2012
IPC:
C07K 16/28 (2006.01), A61K 38/17 (2006.01), A61P 1/00 (2006.01), A61P 11/00 (2006.01), C07K 16/24 (2006.01)
Applicants: FIVE PRIME THERAPEUTICS, INC. [US/US]; Two Corporate Drive South San Francisco, CA 94080 (US) (For All Designated States Except US).
WONG, Brian [US/US]; (US) (For US Only).
GOSLING, Jennifa [US/US]; (US) (For US Only)
Inventors: WONG, Brian; (US).
GOSLING, Jennifa; (US)
Agent: SCARR, Rebecca B.; Casimir Jones, S.C. 2275 Deming Way, Suite 310 Middleton, WI 53562 (US)
Priority Data:
61/432,921 14.01.2011 US
Title (EN) IL-27 ANTAGONISTS FOR TREATING INFLAMMATORY DISEASES
(FR) ANTAGONISTES DE L'IL-27 UTILISABLES EN VUE DU TRAITEMENT DE MALADIES INFLAMMATOIRES
Abstract: front page image
(EN)Methods of treatment using IL-27 antagonists are provided. Such methods include, but are not limited to, methods of treating steroid-resistant conditions, such as asthma, chronic obstructive pulmonary disease (COPD), systemic lupus erythematosus (SLE), and inflammatory bowel disease. Such antagonists include, but are not limited to, antibodies that bind IL-27 and inhibit IL-27-mediated signaling (such as, for example, by blocking binding of IL-27 to its receptor); antibodies that bind the IL-27 receptor, alpha subunit, and inhibit IL-27-mediateed signaling (such as, for example, by blocking binding of IL-27 to the receptor); and soluble forms of IL-27RA.
(FR)L'invention concerne des méthodes de traitement faisant appel à des antagonistes de l'IL-27. Lesdites méthodes comprennent, par exemple, des méthodes de traitement d'affections résistantes aux stéroïdes, comme l'asthme, la bronchopneumopathie chronique obstructive (BPCO), le lupus érythémateux disséminé et les affections intestinales inflammatoires non spécifiques. Ces antagonistes comprennent, mais la liste n'est pas limitative, des anticorps qui se lient à l'IL-27 et inhibent la signalisation à médiation par l'IL-27 (par exemple en bloquant la liaison de l'IL-27 à son récepteur); des anticorps qui se lient à la sous-unité alpha du récepteur de l'IL-27 et inhibent la signalisation à médiation par l'IL-27 (par exemple en bloquant la liaison de l'IL-27 au récepteur); et des formes solubles de l'IL-27RA.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)